Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Statin Therapy to Reduce the Risk of Recurrent Pancreatitis
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Institute Palo Alto
mi
from
Palo Alto, CA
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Statin Therapy to Reduce the Risk of Recurrent Pancreatitis
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Institute Palo Alto
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Statin Therapy to Reduce the Risk of Recurrent Pancreatitis
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Statin Therapy to Reduce the Risk of Recurrent Pancreatitis
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Los Angeles - RHU
mi
from
Los Angeles, CA
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Los Angeles - RHU
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Ucla Dept. Of Medicine
mi
from
Los Angeles, CA
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Ucla Dept. Of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
UCSF Benioff Children's Hospital
mi
from
San Francisco, CA
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
UCSF Benioff Children's Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Nebraska Medical Center
mi
from
Omaha, NE
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Duke Medical Center
mi
from
Durham, NC
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Duke Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Pediatric Specialists
mi
from
Cleveland, OH
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Pediatric Specialists
mi
from
Cleveland, OH
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Children's Medical Center of Dallas
mi
from
Dallas, TX
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Children's Medical Center of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Cliniques Universitaires Saint-Luc
mi
from
Bruxelles,
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Cliniques Universitaires Saint-Luc
mi
from
Bruxelles,
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Children's Hospital GI Nutrition
mi
from
New York, NY
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Children's Hospital GI Nutrition
mi
from
New York, NY
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Georgetown Children's Research Network
mi
from
Washington,
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Georgetown Children's Research Network
mi
from
Washington,
Click here to add this to my saved trials
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center Child Spc
mi
from
Bronx, NY
Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center Child Spc
mi
from
Bronx, NY
Click here to add this to my saved trials
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente
mi
from
Downey, CA
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente
mi
from
Downey, CA
Click here to add this to my saved trials
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente
mi
from
San Diego, CA
Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Prospective Randomized Trial of Anterior Colporrhaphy Versus Cystocele Repair Using Polypropylene Mesh or Porcine Dermis
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente
mi
from
San Diego, CA
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
San Antonio Military Medical Center
mi
from
Forts Sam Houston, TX
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
San Antonio Military Medical Center
mi
from
Forts Sam Houston, TX
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Liver Associates
mi
from
Houston, TX
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Liver Associates
mi
from
Houston, TX
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Texas Liver Institute
mi
from
San Antonio, TX
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Texas Liver Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Mary Immaculate Hospital
mi
from
Newport News, VA
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Mary Immaculate Hospital
mi
from
Newport News, VA
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
St. Mary's Hospital
mi
from
Richmond, VA
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
St. Mary's Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated:  12/31/1969
Antwerp University Hospital (UZA)
mi
from
Edegem,
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Status: Enrolling
Updated: 12/31/1969
Antwerp University Hospital (UZA)
mi
from
Edegem,
Click here to add this to my saved trials
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
Quantitative Ultrasound Spectroscopy to Early HCC
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Palo Alto, CA
B-mode Ultrasound Imaging in Detecting Early Liver Cancer
Quantitative Ultrasound Spectroscopy to Early HCC
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Palo Alto, CA
Click here to add this to my saved trials
To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans
An Eight Week Double Blinded Randomized, Placebo-controlled Trial to Assess the Effect of Two Doses of 100,000 IU Vitamin D3 by Mouth on Select Genetic Responses in Overweight, Hypertensive African-Americans With Hypovitaminosis D
Status: Enrolling
Updated:  12/31/1969
Charles Drew University
mi
from
Los Angeles, CA
To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans
An Eight Week Double Blinded Randomized, Placebo-controlled Trial to Assess the Effect of Two Doses of 100,000 IU Vitamin D3 by Mouth on Select Genetic Responses in Overweight, Hypertensive African-Americans With Hypovitaminosis D
Status: Enrolling
Updated: 12/31/1969
Charles Drew University
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Germantown, TN
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Live Oak, TX
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Live Oak, TX
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
mi
from
Grafton,
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
mi
from
Grafton,
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated:  12/31/1969
Florida Research Institute
mi
from
Lakewood Ranch, FL
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status: Enrolling
Updated: 12/31/1969
Florida Research Institute
mi
from
Lakewood Ranch, FL
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Arkansas Gastroenterology
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Prx Clinical
mi
from
Garden Grove, CA
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Prx Clinical
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Providence Clinical Research
mi
from
North Hollywood, CA
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Providence Clinical Research
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Shahram Jacobs MD, INC
mi
from
Sherman Oaks, CA
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Shahram Jacobs MD, INC
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
Bristol Hospital Dba Connecticut Gastroenterology Institute
mi
from
Bristol, CT
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
Bristol Hospital Dba Connecticut Gastroenterology Institute
mi
from
Bristol, CT
Click here to add this to my saved trials
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated:  12/31/1969
PMG Research of Winston-Salem
mi
from
Winston-Salem, NC
Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)
Status: Enrolling
Updated: 12/31/1969
PMG Research of Winston-Salem
mi
from
Winston-Salem, NC
Click here to add this to my saved trials